Published in Pharma Investments, Ventures and Law Weekly, November 20th, 2005
Total revenue for the third quarter was $10,058,000, a 57% increase from $6,407,000 in the third quarter of 2004. The company posted net income of $2,531,000, or $.22 per diluted share, for the third quarter of 2005, compared to $884,000, or $.08 per diluted share, for the same period last year.
For the 9 months ended September 30, 2005, total revenue increased 30% to $24,369,000 versus $18,810,000 in the comparable period last year. Net income was $5,071,000, or $.44 per diluted share, compared with $9,435,000, or $.83 per...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.